Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT04298034 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Preeclampsia Postpartum Antihypertensive Treatment

Study acronym: P-PAT
StatusActive, Not Recruiting
PhasePhase 3
Started
View on ClinicalTrials.gov ↗

Record History

  1. Completion date: Dec 30, 2025 to Sep 30, 2026v9
  2. Completion date: Jun 30, 2025 to Dec 30, 2025v8
  3. Trial status: Recruiting to Active, Not Recruiting Site details revisedv7 Show 1 more changeShow less
    • Site details revised
  4. Primary and study completion dates: Jun 30, 2024 to Jun 30, 2025v6
  5. Primary completion date: Jun 30, 2022 to Jun 30, 2024 Completion date: Jun 30, 2023 to Jun 30, 2024v5 Show 1 more changeShow less
    • Completion date: Jun 30, 2023 to Jun 30, 2024
Show 3 earlier versionsHide 3 earlier versions
  1. Phase: Not applicable to Phase 3 Eligibility criteria revised · Study title revisedv4 Show 2 more changesShow less
    • Eligibility criteria revised
    • Study title revised

    See this version in full on ClinicalTrials.gov ↗

  2. Trial status: Not Yet Recruiting to Recruiting Study sites: 0 to 1 · Start date changed from estimate of Aug 1, 2020 to Jul 17, 2020 · Interventions: Labetalol, Hydralazine, Nifedipine (Drug) to Labetalol, Nifedipine (Drug)v3 Show 3 more changesShow less
    • Study sites: 0 to 1
    • Start date changed from estimate of Aug 1, 2020 to Jul 17, 2020
    • Interventions: Labetalol, Hydralazine, Nifedipine (Drug) to Labetalol, Nifedipine (Drug)
  3. Start date: Mar 15, 2020 to Aug 1, 2020v2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The goal of this study is to compare whether antihypertensive treatment in the postpartum period decreases postpartum hypertension and its associated maternal morbidity, including risk of readmission and healthcare utilization in comparison with no treatment. Women with preeclampsia diagnosed during the antepartum, intrapartum or postpartum period will be randomized to either initiate antihypertensive treatment or standard of care. We hypothesize that postpartum antihypertensive treatment of patients with preeclampsia will decrease risk of hospital readmission, healthcare utilization and the number of severe range blood pressures at postpartum follow-up visits.
Trial Details
NCT Number NCT04298034
Lead Sponsor Medical College of Wisconsin
Conditions Preeclampsia, Hypertension in Pregnancy
Enrollment 300 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov